Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tedizolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 1.00 |
| ▸ | CALML3 | P27482 | 6/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tedizolid SCHEMBL3807996 | 1.00 | MAOA (1.00) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| Tedizolid SCHEMBL29380875 | 1.00 | MAOA (1.00) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| Tedizolid SCHEMBL29833257 | 1.00 | MAOA (1.00) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| Tedizolid SCHEMBL31385281 | 1.00 | MAOA (1.00) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| Tedizolid SCHEMBL2171154 | 0.97 | MAOA (0.93) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| Tedizolid SCHEMBL28868597 | 0.97 | MAOA (0.93) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL12997800 | 0.94 | MAOA (0.89) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL11982920 | 0.94 | MAOA (0.89) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL1379662 | 0.94 | MAOA (0.89) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL24142416 | 0.93 | MAOA (0.87) | MAOAMAOBCALML3CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1922 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR BIOME APS (DK) | 2026-04-30 | — | — | US | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-04-16 | — | — | US | claimed |
| EP-4705278-A1 | ANTIMICROBIAL CONJUGATED OLIGOELECTROLYTES AS BROAD-SPECTRUM ANTIBIOTICS | The Regents of University of California (US) | 2026-03-11 | — | — | EP | claimed |
| US-12565482-B2 | Tedizolid intermediate and efficient preparation method thereof | NANJING CHEMPION BIOTECHNOLOGY CO., LTD. (CN) | 2026-03-03 | — | — | US | claimed |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4680027-A1 | A METHOD FOR IMPARTING ANTIMICROBIAL PROPERTIES TO A SYNTHETIC SUBSTRATE | Biocompatibility Innovation Srl (IT) | 2026-01-21 | — | — | EP | claimed |
| EP-4677075-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR Biome ApS (DK) | 2026-01-14 | — | — | EP | claimed |
| EP-2393808-B1 | CRYSTALLINE FORM OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | MERCK SHARP & DOHME (US) | 2019-05-08 | — | — | EP | claimed |
| US-20180251482-A1 | FORMS OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | MERCK SHARP & DOHME LLC | 2018-09-06 | — | — | US | claimed |
| JP-4739229-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| EP-1699784-B1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2011-06-29 | — | — | EP | claimed |
| US-7816379-B2 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2010-10-19 | — | — | US | claimed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | claimed |
| EP-1699784-A4 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2008-09-03 | — | — | EP | claimed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | claimed |
| EP-1699784-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | Dong-A Pharmaceutical Co., Ltd. (KR) | 2006-09-13 | — | — | EP | claimed |
| WO-2005058886-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2005-06-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | IL1B, IL5, SERPINB1 | MAOA 416/4885MAOB 46/4885CALML3 1297/4885 |
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | AADAT, NAT1, IDO1 | MAOA 209/4885MAOB 835/4885CALML3 1049/4885 |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | ABCC1, SLC47A2, ABCB1 | MAOA 2458/4885MAOB 1419/4885CALML3 1108/4885 |
| US-20180251482-A1 | FORMS OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN-5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE | ALPI, PYGL, PYGM | MAOA 2612/4885MAOB 3066/4885CALML3 1240/4885 |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | FNTB, PDE7A, TBL3 | MAOA 1993/4885MAOB 1339/4885CALML3 1019/4885 |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | MAOA 4398/4885MAOB 4248/4885CALML3 1992/4885 |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | ALPI, TPI1, SI | MAOA 3819/4885MAOB 3591/4885CALML3 2192/4885 |
| US-12565482-B2 | Tedizolid intermediate and efficient preparation method thereof | DNMT3A, DNMT1, TET1 | MAOA 2104/4885MAOB 2681/4885CALML3 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.